DRUG · Mapped RxNorm record
Alirocumab
Normalized identity: alirocumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes
NCT03344692
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedEffect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Type2 Diabetesunresolved
Interventions
AlirocumabDRUG · verified · RxNorm: alirocumab
PlaceboOTHER
Sponsors & collaborators
Nantes University Hospitallead sponsor
Regeneron Pharmaceuticalscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03344692 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.